Johnson & Johnson ESMO 2026 plans centre on more than 25 abstracts from the company’s solid tumor portfolio and pipeline, according to a press release dated October 23, 2026, from New Brunswick, N.J. Johnson & Johnson (NYSE:JNJ) will present at the European Society for Medical Oncology (ESMO) Congress. The slate covers a novel therapeutic modality in advanced prostate cancer, fresh data in head and neck, lung, colorectal and bladder cancers, and late-breaking Phase 3 findings in high-risk localized and locally advanced prostate cancer.
The company describes the presentations as research across the continuum of cancer care, from earlier disease stages to advanced settings. Per the release, the work builds on evidence for established medicines while advancing investigational approaches aimed at areas of continued unmet need. This report on Johnson & Johnson ESMO 2026 relies solely on that company release, and ESMO session dates and times are not disclosed in it.
Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, said the company aims to “redefine how cancer is treated” by intervening earlier, improving the treatment experience and pursuing new biological approaches. He added that the breadth of evidence reflects progress toward helping people live longer and better. These are company statements, and the release contains no numerical efficacy results for any abstract.
Johnson & Johnson ESMO 2026 Abstracts Span Five Solid Tumor Types
The Johnson & Johnson ESMO 2026 abstract list is grouped by tumor type in the release, with prostate, head and neck, and lung presentations itemized individually. Four prostate entries are listed: a proffered paper on JNJ-6143, a late-breaking PROTEUS substudy, a longer-term PROTEUS poster, and trial-in-progress ePosters for pasritamig. Colorectal and bladder cancer are named in the program summary, but the release does not itemize specific abstracts for them.
Counting the entries named in the release, five head and neck and lung presentations sit alongside the prostate items, so the release itemizes only a subset of the more than 25 abstracts. Formats vary widely, including proffered papers, late-breaking abstracts, posters, ePosters, and rapid oral presentations. Readers who need the full list should consult the company’s ESMO 2026 curtain raiser, which the release names as the source for sponsored abstracts.
The headline for the Johnson & Johnson ESMO 2026 package is the first readout following the company’s acquisition of the RIPTAC platform. The release says that readout shows promising anti-tumor activity with JNJ-6143 in difficult-to-treat prostate cancer, alongside new first-line head and neck data for RYBREVANT FASPRO and new ERLEADA substudy findings that build on primary results shown at ASCO 2026. The release does not publish the underlying response rates.
Johnson & Johnson ESMO 2026 Prostate Data: JNJ-6143, ERLEADA and Pasritamig
JNJ-6143 (formerly HLD-0915) is a first-in-class oral RIPTAC small molecule, and at Johnson & Johnson ESMO 2026 its safety and efficacy results mark the first presentation since the acquisition of Halda Therapeutics (Proffered Paper #2216O). The results will inform the optimal dose for further development in metastatic androgen pathway modulation-resistant prostate cancer, also called metastatic castration-resistant prostate cancer. The company describes the molecule as a targeted dual-protein lock that joins the survival protein BRD4 with the tumor-selective androgen receptor.
JNJ-6143 is once-daily and oral, and the release calls it the first investigational compound from the RIPTAC platform to reach clinical studies. It is being evaluated in a Phase 1 trial (NCT06800313) and a Phase 2 trial (NCT07832292) in metastatic prostate cancer. Johnson & Johnson completed its acquisition of Halda Therapeutics in December 2025, adding the platform to its oncology portfolio.
ERLEADA (apalutamide) is the second pillar of the Johnson & Johnson ESMO 2026 prostate program. The late-breaking PROTEUS substudy (Abstract #53) tests perioperative ERLEADA plus androgen deprivation therapy with radical prostatectomy against surgery alone, and a poster (#2049P) reports longer-term PROTEUS outcomes. ERLEADA won U.S. approval for non-metastatic castration-resistant disease in February 2018 and metastatic castration-sensitive disease in September 2019, and more than 380,000 patients worldwide have received it. Pasritamig (JNJ-78278343), a KLK2-targeted T-cell-redirecting bispecific antibody, appears through trial-in-progress ePosters.
Johnson & Johnson ESMO 2026 Head and Neck and Lung Data for RYBREVANT FASPRO
In head and neck cancer, the OrigAMI-4 Phase 1b/2 study reports first results with investigational subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus pembrolizumab and carboplatin chemotherapy as first-line treatment for recurrent or metastatic disease, with encouraging overall response rates (Rapid Oral #1539RO). A poster (#1585P) uses an indirect comparison to show improved overall survival, progression-free survival and time to next treatment versus real-world therapies after immunotherapy and platinum chemotherapy. The FDA has granted RYBREVANT FASPRO Breakthrough Therapy Designation and Priority Review in previously treated head and neck cancer.
The lung program adds three entries. The Phase 2 COCOON cohort studies prevention of moderate-to-severe dermatologic adverse events with first-line RYBREVANT FASPRO plus LAZCLUZE (lazertinib) in EGFR-mutated non-small cell lung cancer (#2700RO), while post hoc MARIPOSA analyses examine dose modifications (#2650P). The MyChoice interim analysis (#2641P) is described as the largest evaluation of patient and physician treatment preferences in first-line metastatic common EGFR-mutated disease.
Background in the release shows why the Johnson & Johnson ESMO 2026 lung data matter. RYBREVANT FASPRO received U.S. FDA approval in December 2025, is the only subcutaneous therapy approved for the listed EGFR-mutated populations, and allows once-monthly dosing after initial weekly dosing. It uses Halozyme’s ENHANZE technology. NCCN Guidelines list amivantamab plus lazertinib as a Category 1 preferred first-line option for specified EGFR mutations, and LAZCLUZE is licensed from Yuhan Corporation under a 2018 agreement.
Itemized ESMO 2026 abstracts
| Asset | Tumor type | Study | Format | Abstract # |
|---|---|---|---|---|
| JNJ-6143 | Prostate (mAPMR/mCRPC) | Safety and efficacy, dose selection | Proffered Paper | 2216O |
| ERLEADA | Prostate (high-risk localized/locally advanced) | PROTEUS substudy (Phase 3) | Late-Breaking Abstract | 53 |
| ERLEADA | Prostate | PROTEUS longer-term results (Phase 3) | Poster | 2049P |
| Pasritamig | Prostate (mAPMR) | KLK2-comPAS, comPAS2, KLK2-PASenger | ePoster (trial-in-progress) | 2388eTiP, 2387eTiP |
| RYBREVANT FASPRO | Head and neck | OrigAMI-4 (Phase 1b/2) | Rapid Oral | 1539RO |
| RYBREVANT FASPRO | Head and neck | Indirect comparison vs real-world therapies | Poster | 1585P |
| RYBREVANT FASPRO + LAZCLUZE | Lung (EGFR NSCLC) | COCOON (Phase 2) | Rapid Oral | 2700RO |
| RYBREVANT + LAZCLUZE | Lung (EGFR NSCLC) | MARIPOSA post hoc (Phase 3) | Poster | 2650P |
| Not applicable | Lung (EGFR NSCLC) | MyChoice interim | Poster | 2641P |
Product profiles from the release
| Product | Type | Status | Key facts |
|---|---|---|---|
| JNJ-6143 (formerly HLD-0915) | Oral RIPTAC small molecule | Investigational | Binds AR to sequester BRD4; Phase 1 NCT06800313, Phase 2 NCT07832292 |
| ERLEADA (apalutamide) | Androgen receptor inhibitor | Approved | FDA nmCRPC Feb 2018; mCSPC Sep 2019; more than 380,000 patients treated |
| Pasritamig (JNJ-78278343) | KLK2 x CD3 bispecific antibody | Investigational | Evaluated in pretreated mCRPC |
| RYBREVANT FASPRO | Subcutaneous amivantamab and hyaluronidase-lpuj | Approved (EGFR NSCLC); head and neck investigational | FDA approval Dec 2025; Breakthrough Therapy Designation and Priority Review in head and neck |
| LAZCLUZE (lazertinib) | Oral third-generation EGFR TKI | Approved | Licensed from Yuhan Corporation in 2018 |
| Halda Therapeutics | Acquired company | Acquisition completed Dec 2025 | Added JNJ-6143 and the RIPTAC platform |
